Prognostic predictors of gastrointestinal stromal tumors: a multi-institutional analysis of 102 patients with definition of a prognostic index

Kontogianni, Konstantina; Demonakou, Maria; Kavantzas, N; Lazaris, Andreas C.; Lariou, Konstantia; Vourlakou, Christina; Davaris, Panagiotis

doi:10.1016/s0748-7983(03)00073-8

Cited by 21 publications

(22 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, Bcl-2 would not be useful to predict response to imatinib. Indeed, most of the studies could not associate the highly expressed Bcl-2 to other prognostic factors or to drug response in GIST [22][23][24]34 . We confirmed that Bcl-2 assessment could not improve staging or prognosis assessment in GIST.…”

Section: Discussionmentioning

confidence: 99%

Ki-67 expression score correlates to survival rate in gastrointestinal stromal tumors (GIST)

et al. 2012

View full text Add to dashboard Cite

PURPOSE: To evaluate the immunohistochemical expression of p16, Ki-67, p53 and Bcl-2 proteins in gastrointestinal stromal tumors (GIST); to assess the possible association between these variables and clinical and histopathological factors of cancer; and to check for prognostic value of these variables (survival and recurrence). METHODS: A sample of 55 patients treated surgically for GIST in three hospitals was studied. The surgically excised tumors were confirmed as GIST by KIT, vimentin, desmin S100 protein, CD117, 1A4 and CD34 assessment in paraffin blocks. RESULTS: Only 9 (16%) cases of GIST were positive for p53, p16 was positive among 43.6%; 80% of GISTs showed staining for Bcl-2. The proliferative index (expressed as the proportion of positive cells) assessed by immunohistochemical expression of Ki-67 was high in 49% of cases. Elevated Ki-67 scores were associated to high histological grade (p=0.0026) and mitosis index, MI (p=0.0001). High Ki-67 index was associated to death. Expression of p53, p16 and Bcl-2 did not correlate to morphological or clinical variables. CONCLUSIONS: Ki-67 immunohistochemical evaluation should be included in preoperative evaluation of GIST biopsies or surgical specimens as a prognostic tool for clinical staging; and all other proteins studied (Bcl-2, p53 and p16) did not play a role in GIST metabolic or carcinogenic process, remaining without prognostic value.

show abstract

Section: Discussionmentioning

confidence: 99%

Ki-67 expression score correlates to survival rate in gastrointestinal stromal tumors (GIST)

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The mitotic index has been implicated in the proliferate activities of tumor, and considered as a variable to determine the histological grade of the tumor (van Diest et al 1998) in stomach cancer (Takahashi et al 2003). Kontogianni et al (2003) found that tumor size, necrosis, mitoses, metastasis and PCNA labeling index are correlated as independent poor prognostic factors in GITC. The mitotic activity as an independent prognostic variable is currently used in the tumor-grading system (Medri et al 2003).…”

Section: Discussionmentioning

confidence: 99%

Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas

Montero

Abreu

Tonino

2007

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…In humans, tumor site (intestines vs stomach), tumor size ( 2 cm), and mitotic index (<5 mitoses per 50 high-powered fields [HPF]) have been shown to be the most significant prognostic indicators. 7,9,[15][16][17]26,28 Cellular proliferation analysis, as determined by Ki67 and argyrophilic nuclear organizer regions (AgNOR) staining, also seem to provide predictive value. 22 No such correlations have been made for canine GISTs.…”

mentioning

confidence: 99%

Canine Gastrointestinal Stromal Tumors

Gillespie

Baer²,

Farrelly

et al. 2010

Vet Pathol

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GISTs), leiomyomas, and leiomyosarcomas are common mesenchymal neoplasms in the gastrointestinal (GI) tract of dogs. As previously diagnosed smooth muscle tumors of the canine GI tract are increasingly reclassified as GISTs, it becomes important to identify additional criteria that may assist in the diagnosis of these neoplasms, provide prognostic information, and offer targets for therapy. Examination of cluster of differentiation (CD), molecule expression (such as KIT [CD117] and CD34) as well as gross, histologic, and immunohistochemical features (such as tumor size, tumor location, mitotic index, AgNOR, and Ki67 labeling) in human GISTs has revealed new and valuable prognostic, diagnostic, and therapeutic information. In this study, GISTs were examined for the gross, histologic, and immunohistochemical features listed above. Forty-nine cases of canine gastrointestinal mesenchymal neoplasms from the Animal Medical Center (New York, NY) were categorized as GISTs (KIT positive), leiomyosarcoma/leiomyoma (KIT negative, smooth muscle actin [SMA], and/or desmin positive), or other (KIT, SMA, and desmin negative). A proportion (55%) of canine cases previously diagnosed as smooth muscle tumors were reclassified as GISTs according to KIT immunoreactivity. Statistical correlations with survival data were not possible because of insufficient follow-up data. However, there was a significant difference between mitotic index, AgNOR, and Ki67 scores depending on the location of the tumor (small vs large intestine). This study represents the first time CD34 immunoreactivity has been demonstrated in canine GISTs.

show abstract

Prognostic predictors of gastrointestinal stromal tumors: a multi-institutional analysis of 102 patients with definition of a prognostic index

Cited by 21 publications

References 23 publications

Ki-67 expression score correlates to survival rate in gastrointestinal stromal tumors (GIST)

Ki-67 expression score correlates to survival rate in gastrointestinal stromal tumors (GIST)

Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas

Canine Gastrointestinal Stromal Tumors

Contact Info

Product

Resources

About